Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Regulatory T Cell Depletion With Denileukin Diftitox Followed by Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox-Tricom in Patients With Advanced or Metastatic Malignancies Expressing CEA

NCT00128622 is registered in ClinicalTrials.gov with H. Kim Lyerly as lead sponsor.

NCT NCT00128622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Regulatory T Cell Depletion With Denileukin Diftitox Followed by Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox-Tricom in Patients With Advanced or Metastatic Malignancies Expressing CEA
Lead sponsor
H. Kim Lyerly
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2005
Completion date
May 31, 2009
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, lung cancer, pancreatic cancer, unspecified adult solid tumor, protocol specific